Drug Trial Radar · NCT01678599
Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease
Last checked: Nov 20, 2026Latest source record: Jun 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Apr 2011
Primary completion
Dec 2012
Study completion Apr 2013
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medecins Sans Frontieres, Netherlands
- First posted
- Sep 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to estimate the gain in sensitivity of several multiple-sample strategies of PCR samples with respect to the current standard (single sample of 10 ml) to detect Chagas chronic stage at baseline and to identify the optimal sampling strategy based on the sensitivity, cost,the completeness of sampling and the acceptability for study patients.
Conditions
- Chagas Disease
Interventions
BenznidazoleDrug
All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoints are: - A positive or negative PCR at baseline (BL) among serology positive patients.Time frame: Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits.
- - Identification of the optimal relationship between sensitivity and feasibility at baseline.Time frame: Bloods will be at baseline and EOT (last day of treatment +10 + 5 days), 6 months and 12 months follow-up visits.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medicin Sans Frontièrs (MSF)
Aiquile, Bolivia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.